BiotechTube
Neutrolis

Neutrolis

Cambridge, United States· Est.
neutrolis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Neutrolis is pioneering a novel therapeutic approach focused on Neutrophil Extracellular Traps (NETs), which are implicated in a range of autoimmune, inflammatory, thrombotic, and oncologic diseases. Founded in 2017 by leading NETosis researchers and backed by $45M in funding, the company has advanced into clinical stages with its exDNASE™ platform. Neutrolis aims to transform patient care by developing precision therapies that degrade pathologic NETs, starting with lupus, offering a potential paradigm shift from broad immunosuppression to targeted disease modification.

Autoimmune DiseasesInflammatory DiseasesThrombosisOncology

Technology Platform

The exDNASE™ platform engineers novel enzyme molecules designed to specifically penetrate, degrade, and disassemble Neutrophil Extracellular Traps (NETs). It is supported by proprietary NET biomarker technology for patient stratification.

Funding History

1
Total raised:$10M
Seed$10M

Opportunities

The company is targeting a fundamental mechanism (NETosis) implicated in a vast range of high-prevalence diseases, including lupus, rheumatoid arthritis, thrombosis, and cancer metastasis, representing multi-billion dollar markets.
Its precision medicine approach, guided by proprietary biomarkers, could enable superior efficacy in defined patient populations and support premium pricing.

Risk Factors

The core scientific hypothesis—that degrading NETs will yield significant clinical benefit—remains unproven in human trials.
The company faces competition from other approaches targeting NET formation or components, and as a pre-revenue, private biotech, it carries significant financing and execution risk for advancing clinical programs.

Competitive Landscape

The competitive field for NET-targeting therapies is emerging and includes companies developing PAD4 inhibitors to prevent NET formation, neutrophil elastase (NE) inhibitors, and other DNase-based approaches. Neutrolis differentiates itself with its engineered exDNASE™ platform specifically designed for the complex structure of pathologic NETs and its integrated biomarker strategy.

More companies in United States →